ライフサイエンスコーパス: occluder

1 an intentional agent launch a ball behind an occluder.

2 ' representation of what happened behind the occluder.

3 losed using an off-the-shelf nitinol cardiac occluder.

4 as endovascularly closed using the Amplatzer occluder.

5 to the emergence of a target from behind an occluder.

6 t direction when the finger passed behind an occluder.

7 nd stenosis was achieved in the LCX with the occluder.

8 e virtual fingertip while it moved behind an occluder.

9 uccessful deployment of the Amplatzer Septal Occluder.

10 ect was then closed with an Amplatzer Septal Occluder.

11 onary artery in dogs was produced by a screw occluder.

12 cluded object appears to continue behind its occluder.

13 mm apart on the button loop attached to the occluder.

14 etion occurs when a contour passes behind an occluder.

15 nd left atrial catheters and coronary artery occluders.

16 h in CL conditions, with or without hoods or occluders.

17 ccess ports were closed with nitinol cardiac occluders.

18 our had placement of thoracic aortic balloon occluders.

19 nic lung lymph fistulas and pulmonary venous occluders.

20 ted complications were higher for the Amulet occluder (4.5% versus 2.5%), largely related to more fre

21 d the safety and effectiveness of the Amulet occluder (Abbott) in patients with nonvalvular atrial fi

22 ults of the multicenter USA Amplatzer ductal occluder (ADO) device trial.

23 VSDs) using the new Amplatzer Membranous VSD Occluder (AGA Medical Corp., Golden Valley, Minnesota) i

24 defects (VSDs) using the new Amplatzer mVSD occluder (AGA Medical Corp., Golden Valley, Minnesota).

25 sachusetts] and Amplatzer PFO Occluder [disc occluder] [AGA Medical/St. Jude Medical, St. Paul, Minne

26 A transcatheter occluder (Amplatzer Septal Occluder) with a trailing pre

27 dogs was encircled (day 0) with a hydraulic occluder and ameroid constrictor to enable reversible an

28 ed complications were higher with the Amulet occluder and decreased with operator experience.

29 lly instrumented with a reversible hydraulic occluder and Doppler flowmeter to study RII (n = 8).

30 Eighteen swine with a hydraulic occluder and flow probe on the circumflex artery underwe

31 ontaining devices, such as the Amplatzer PFO Occluder and Gore Cardioform Septal Occluder, are used f

32 ry artery stenosis was induced by an ameroid occluder and maintained for 1 or 2 weeks (end point) in

33 izes an object when it moves behind a static occluder and only a small fragment of its shape is visib

34 In several active conditions, the spot, occluder and shape translated such that when subjects tr

35 primarily reflected interactions between the occluder and the remaining body features.

36 -term safety and effectiveness of the Amulet occluder and Watchman 2.5 devices.

37 o 5 minutes later followed by release of the occluders and rewarming.

38 umented with a Doppler flow probe, hydraulic occluder, and indwelling catheter on the left anterior d

39 ted with a Doppler velocity probe, hydraulic occluder, and indwelling microcatheter in the left anter

40 12 dogs was instrumented with a flow probe, occluder, and intracoronary pressure catheter, and non-f

41 atrial septal defect devices, patent ductus occluders, and stents to treat coarctation of the aorta.

42 device implantation attempt (n = 917, Amulet occluder; and n = 916, Watchman device).

43 ng whether two line segments separated by an occluder are collinear.

44 ed by the intersection of the object and the occluder are generally not consistent with the direction

45 of transcatheter atrial septal defect (ASD) occluders are currently in use around the world.

46 the responses to the occluded shape and the occluders are weighted separately and linearly combined.

47 tzer PFO Occluder and Gore Cardioform Septal Occluder, are used for transcatheter patent foramen oval

48 were chronically instrumented with a balloon occluder around a branch of the left coronary artery and

49 zed and fitted with an extravascular balloon occluder around the brachiocephalic artery using aseptic

50 terization and implantation of extravascular occluder around the brachiocephalic artery.

51 od flow was controlled by use of a hydraulic occluder around the left iliac artery.

52 , and 9 months after placement of an ameroid occluder around the proximal left circumflex coronary ar

53 and clinical utility of the Amplatzer septal occluder (ASO) for closure of secundum atrial septal def

54 , a cube, positioned at the other end of the occluder began flickering.

55 l after ASD closure with an Amplatzer septal occluder (cases) were compared with controls (matched 2:

56 ith Migraine and PFO Using the Amplatzer PFO Occluder Compared to Medical Management] studies).

57 of the dual-seal mechanism of the Amulet LAA occluder compared with the Watchman device.

58 automated servo-controlled inflation of the occluder cuff (n = 8).

59 ion (term is ca 145 days) with an inflatable occluder cuff around the umbilical cord, amniotic and fe

60 Automated servo-controlled inflation of the occluder cuff, programmed to reduce umbilical blood flow

61 erapy and PFO closure with the Amplatzer PFO Occluder device (St.

62 The HSO is a low-profile, double-disk occluder device for percutaneous closure of secundum ASD

63 balloon-sized ASD diameter, Amplatzer septal occluder device size, and device size-ASD diameter diffe

64 In analyses limited to the 2 disc occluder device trials, the effect of closure was not si

65 ther the Amplatzer or Gore Cardioform Septal Occluder device.

66 after ASD closure with the Amplatzer septal occluder device.

67 SD device closure by the new DAS-Angel Wings occluder device.

68 oth the Amplatzer and Gore Cardioform Septal Occluder devices demonstrated comparable safety and effi

69 nt of septal communications using either new occluder devices or novel techniques.

70 c., Boston, Massachusetts] and Amplatzer PFO Occluder [disc occluder] [AGA Medical/St. Jude Medical,

71 en a moving target is hidden from view by an occluder during a portion of its trajectory, the bat con

72 g before, during, and after inflation of the occluder for 15 minutes was 35+/-5%, 1+/-8%, and 21+/-10

73 ision deprived in one eye with a translucent occluder for 5 days.

74 patients implanted with the AMPLATZER Septal Occluder for percutaneous closure of secundum atrial sep

75 ulticenter Pivotal Study of the HELEX Septal Occluder for Percutaneous Closure of Secundum Atrial Sep

76 old chicks by the application of translucent occluders for 10 days and was followed by unrestricted v

77 sure catheters and inferior vena caval (IVC) occluders; four had placement of thoracic aortic balloon

78 e of patients were free of OAC in the Amulet occluder group at each follow-up visit, with 94.0% and 9

79 The Clamshell Septal Occluder has been used to close various congenital heart

80 the safety and efficacy of the HELEX septal occluder (HSO) with surgical repair of atrial septal def

81 rial (Amplatzer Amulet Left Atrial Appendage Occluder IDE Trial) was designed to evaluate the safety

82 examine the effectiveness and safety of this occluder in an animal model.

83 ty and effectiveness of the AMPLATZER Septal Occluder in clinical practice are not available.

84 The Helex septal occluder is a new type of device designed to improve the

85 tal defects (ASD) using the Amplatzer septal occluder is generally safe and effective, but erosion in

86 cluding material, although these fail if the occluder is opaque.

87 Closure of ASD with the HELEX septal occluder is safe and effective when compared with surgic

88 rial septal defect with the AMPLATZER Septal Occluder is safe and effective.

89 The Bard Clamshell Septal Occluder is well tolerated in the canine heart for at le

90 (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] T

91 rial (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] T

92 ith a coronary artery BF probe and hydraulic occluder, left ventricular (LV) pressure gauge, and wall

93 = 63) compared with patients with the Amulet occluder (n = 31).

94 right atrial catheter in animals with an LCx occluder (n=2).

95 cluded data on 2 devices (STARFlex [umbrella occluder] [NMT Medical, Inc., Boston, Massachusetts] and

96 ted with a risk of bleeding, devices such as occluders of a PFO or the left atrial appendage are pref

97 otid occlusion was elicited with a hydraulic occluder on the common carotid artery.

98 Twenty-eight weeks later, we placed an occluder on the descending thoracic aorta and inferior v

99 from rising during air breathing by using an occluder on the dorsal aorta.

100 ally instrumented pigs (n = 18) with a fixed occluder on the proximal left anterior descending corona

101 Hydraulic occluders on the thoracic aorta and inferior vena cava w

102 patent foramen ovale with the Amplatzer PFO Occluder or to receive medical therapy.

103 plantation of a LAA occluder with the Amulet occluder or Watchman device.

104 additional group was raised with opaque eye occluders over the right eye for 12 hours daily.

105 regional coronary occlusion using an ameroid occluder placed around the left anterior descending coro

106 The Helex septal occluder proved safe and effective for ASD closure.

107 The dual-seal Amulet occluder reduces atrial fibrillation-related thromboembo

108 Percutaneous closure using occluders specifically designed to improve closure and r

109 eye growth: form deprivation by translucent occluders, spherical defocus by -10- or +10-D lenses, an

110 LAA occlusion was higher for the Amulet occluder than for the Watchman device (98.9% versus 96.8

111 These frames demonstrated septal defect occluders that were designed based on a patient's cardia

112 nal transducer to activate the putative pore-occluder, the alpha(1C) I-II intracellular linker.

113 article include the angled Amplatzer Ductal Occluder, the cribriform atrial septal defect device for

114 wall against the septum and left ventricular occluder, thereby obliterating the VSD.

115 2 randomized trials using the Amplatzer PFO Occluder to assess the efficacy and safety of percutaneo

116 was surgically instrumented with an ameroid occluder to induce CCO; 8 weeks after surgery, animals w

117 ith Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management [PREMIUM]; NCT00355056).

118 ith Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management) was a double-blind study

119 By graded inflation of the occluder to produce a wide range of coronary stenosis se

120 re products available such as e.g. Amplatzer occluder to simplify the procedure and shorten the durat

121 ccluding one eye for 24 hours, switching the occluder to the fellow eye for the next 24 hours, and re

122 mplications, using permeable nitinol cardiac occluders to close the access ports, were common but acc

123 perseded the previously popular Rashkind PDA occluder (USCI/Bard, Tewksbury, MA) because of significa

124 e Vascular Plug 3, Ventricular Septal Defect Occluder, Vascular Plug 2, and Paravalvular Leak Device

125 Adaptica) uses a novel infrared-transmitting occluder wand to quickly estimate intermittent deviation

126 tal defect closure with the AMPLATZER Septal Occluder was attempted in 1000 patients (aged 0.3-83.6 y

127 In 11 pigs, a hydraulic occluder was inflated distal to the flow probe.

128 The hydraulic occluder was inflated to induce a stable 41+/-4% reducti

129 A vascular occluder was inserted in 34 pigs, and they were assigned

130 The Amulet occluder was noninferior for safety and effectiveness of

131 The Amulet occluder was noninferior to the Watchman device for the

132 The Amulet occluder was noninferior to the Watchman device for the

133 used as sham-operated controls in which the occluder was not inflated throughout the protocol.

134 A hydraulic occluder was placed in the left circumflex coronary arte

135 A vascular occluder was positioned distal to the flow probe for flo

136 The occluder was then deflated allowing return of umbilical

137 One hour later, the occluder was withdrawn, and reperfusion was maintained f

138 formation loss and clutter introduced by the occluder, we found that reductions in response strength

139 Strokes in patients with the Amulet occluder were less severe (n = 38, nondisabling; n = 11,

140 riving pressure was altered by inflating the occluders while adenosine was infused into the left atri

141 o undergo percutaneous implantation of a LAA occluder with the Amulet occluder or Watchman device.

142 randomized LAAO trial, comparing the Amulet occluder with the Watchman 2.5 device (Boston Scientific

143 A transcatheter occluder (Amplatzer Septal Occluder) with a trailing premounted suture was deployed

144 s (access and closure with a nitinol cardiac occluder without death or emergency surgical rescue) occ